NorthCoast Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

NorthCoast Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-6,380	Closed	-$454K	–	253
2019 Q2	$454K	Sell	6,380 -457	-7%	-$33.7K	0.03%	213
2019 Q1	$536K	Buy	+6,837	New	+$518K	0.04%	188

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

NorthCoast Asset Management's LGND Position: Q3 2019 in Review

NorthCoast Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2019, closing a stake of 6,380 shares — an estimated $454K sold.

NorthCoast Asset Management first reported a position in LGND in Q1 2019 and held it in 2 quarters. The position peaked at $536K in Q1 2019. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

NorthCoast Asset Management reported no remaining Ligand Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
NorthCoast Asset Management sold 6,380 Ligand Pharmaceuticals shares in Q3 2019, an estimated $454K.
NorthCoast Asset Management first reported a position in Ligand Pharmaceuticals in Q1 2019 and held it in 2 quarters.
NorthCoast Asset Management's Ligand Pharmaceuticals position peaked at $536K in Q1 2019.
275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on NorthCoast Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.